TSTickerStarGet alerts

Evommune Enters into Agreement to In-License EVO570, a Potential Best-in-Class Oral VAV1 Molecular Glue Degrader, from Hinova Pharmaceuticals

(EVMN) Skip to main content Skip to section navigation Skip to footer chevron_left Back to Evommune.com Check Out the EADV Webinar of Full Phase 2 Data for Oral MRGPRX2 Inhibitor EVO756 in Chronic Inducible Urticaria.

Share this story

What matters

(EVMN) Skip to main content Skip to section navigation Skip to footer chevron_left Back to Evommune.com Check Out the EADV Webinar of Full Phase 2 Data for Oral MRGPRX2 Inhibitor EVO756 in Chronic Inducible Urticaria.

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open Investor relations

Follow EVMN in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert